1. Home
  2. WDH vs SION Comparison

WDH vs SION Comparison

Compare WDH & SION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WDH
  • SION
  • Stock Information
  • Founded
  • WDH 2016
  • SION 2019
  • Country
  • WDH China
  • SION United States
  • Employees
  • WDH N/A
  • SION N/A
  • Industry
  • WDH Specialty Insurers
  • SION
  • Sector
  • WDH Finance
  • SION
  • Exchange
  • WDH Nasdaq
  • SION NYSE
  • Market Cap
  • WDH 564.5M
  • SION 583.9M
  • IPO Year
  • WDH 2021
  • SION 2025
  • Fundamental
  • Price
  • WDH $1.49
  • SION $10.46
  • Analyst Decision
  • WDH
  • SION Strong Buy
  • Analyst Count
  • WDH 0
  • SION 1
  • Target Price
  • WDH N/A
  • SION $32.00
  • AVG Volume (30 Days)
  • WDH 422.9K
  • SION 235.8K
  • Earning Date
  • WDH 03-12-2025
  • SION 03-20-2025
  • Dividend Yield
  • WDH 2.42%
  • SION N/A
  • EPS Growth
  • WDH 150.00
  • SION N/A
  • EPS
  • WDH 0.14
  • SION N/A
  • Revenue
  • WDH $379,748,325.00
  • SION N/A
  • Revenue This Year
  • WDH N/A
  • SION N/A
  • Revenue Next Year
  • WDH $10.19
  • SION N/A
  • P/E Ratio
  • WDH $9.49
  • SION N/A
  • Revenue Growth
  • WDH 5.36
  • SION N/A
  • 52 Week Low
  • WDH $0.97
  • SION $10.27
  • 52 Week High
  • WDH $1.57
  • SION $25.19
  • Technical
  • Relative Strength Index (RSI)
  • WDH 57.08
  • SION N/A
  • Support Level
  • WDH $1.19
  • SION N/A
  • Resistance Level
  • WDH $1.57
  • SION N/A
  • Average True Range (ATR)
  • WDH 0.12
  • SION 0.00
  • MACD
  • WDH -0.01
  • SION 0.00
  • Stochastic Oscillator
  • WDH 73.55
  • SION 0.00

About WDH Waterdrop Inc. (each representing the right to receive 10)

Waterdrop Inc is a technology platform dedicated to insurance and healthcare service. It is a third-party insurance platform in China in terms of life and health insurance.

About SION SIONNA THERAPEUTICS INC

Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which Heads to insufficient CFTR function.

Share on Social Networks: